header image

Noticias Recientes

Update of Summary of Product Characteristics for Nuwiq® includes data on effective bleed protection with twice-weekly dosing with personalised prophylaxis

30.09.2019

Octapharma announced today that the European Medicines Agency has authorised an updated Summary of Product Characteristics (SmPC) for Nuwiq® that includes information on personalised prophylaxis in patients with haemophilia A....

Octapharma to Present New Data on Management of People with Haemophilia A or von Willebrand Disease at ISTH 2019

02.07.2019

New scientific data on Octapharma’s Haematology portfolio will be presented at the upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Melbourne, Australia, from 6 to 10 July...

Octapharma Group reports strong results for 2018

14.03.2019

Reporting revenue of €1.8 billion and operating income of €346 millionGroup sales increased 4.5% compared to 2017 (on a constant currency basis, the growth rate is 6.6%)All our products performed well, but to be highlighted are...